Pharmacokinetics of Anti‐VEGF Agent Aflibercept in Cancer Predicted by Data‐Driven, Molecular‐Detailed Model

Publisher： John Wiley & Sons Inc

E-ISSN： 2163-8306|4|11|641-649

ISSN： 2163-8306

Source： Cpt: Pharmacometrics & Systems Pharmacology, Vol.4, Iss.11, 2015-11, pp. : 641-649

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug

By  

Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol. 10, Iss. 6, 2011-12 ,pp. : 497-508

Bentham Science Publishers

Access to resources Recommend Favorite

Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors

By  

Mini Reviews in Medicinal Chemistry, Vol. 13, Iss. 4, 2013-04 ,pp. : 530-540

Bentham Science Publishers

Access to resources Recommend Favorite

Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer

By Troiani Teresa   Martinelli Erika   Orditura Michele   De Vita Ferdinando   Ciardiello Fortunato   Morgillo Floriana  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 7, 2012-07 ,pp. : 949-959

Informa Healthcare

Access to resources Recommend Favorite

Resistance to Anti-VEGF Agents

By  

Current Pharmaceutical Design, Vol. 10, Iss. 1, 2004-01 ,pp. : 51-64

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-VEGF Treatment of Corneal Neovascularization

By Keating Anne M.   Jacobs Deborah S.  

The Ocular Surface, Vol. 9, Iss. 4, 2011-10 ,pp. : 227-238

Ethis Communications

Access to resources Recommend Favorite